Why Regeneron Pharmaceuticals Stock Topped the Market on Tuesday

News of a significant earnings beat propelled Regeneron Pharmaceuticals (NASDAQ: REGN) to a nearly 5% share price gain on the second trading day of the week. The company posted its fourth-quarter and full-year 2024 results before market open, and investors were clearly impressed by the numbers. Regeneron's price zoomed well higher than the S&P 500 index's trajectory, which was a rise of 0.7% on the day.The quarter saw Regeneron grow its revenue by 10% year over year to just under $3.79 billion. Although non-GAAP (adjusted) net income didn't rise as precipitously, it did improve, gaining 2% to $1.39 billion. The latter figure shook out to $12.07 per share. That meant a double beat for the pharmaceutical company, especially on the bottom line, as analyst expectations for the period were more modest. Collectively, they were anticipating Regeneron would book $3.76 billion in revenue, filtering down to adjusted net income of $11.27 per share. Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool